CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
Some three months after the company first disclosed partnership interest, CRISPR Therapeutics board member and SR One CEO Simeon George, M.D., says it’s “still early days” for sealing new deals.
Artificial intelligence (AI) isn't the only industry with explosive growth potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results